Compare Stocks

Date Range: 

 Kiniksa PharmaceuticalsPhathom PharmaceuticalsPliant TherapeuticsNorthwest BiotherapeuticsInnoviva
SymbolNASDAQ:KNSANASDAQ:PHATNASDAQ:PLRXOTCMKTS:NWBONASDAQ:INVA
Price Information
Current Price$14.53$34.83$32.84$1.44$11.76
52 Week RangeBuyBuyBuyN/ASell
MarketRank™
Overall Score1.71.82.00.51.1
Analysis Score3.53.33.50.00.5
Community Score2.42.54.62.72.1
Dividend Score0.00.00.00.00.0
Ownership Score2.52.51.70.01.7
Earnings & Valuation Score0.00.60.00.01.3
Analyst Ratings
Consensus RecommendationBuyBuyBuyN/ASell
Consensus Price Target$37.00$53.00$49.20N/A$10.00
% Upside from Price Target154.65% upside52.17% upside49.82% upsideN/A-14.97% downside
Trade Information
Market Cap$997.55 million$1.05 billion$1.14 billion$1.22 billion$1.17 billion
Beta0.031.32N/A0.930.64
Average Volume480,184101,809157,9182,114,236538,747
Sales & Book Value
Annual RevenueN/AN/A$57.05 million$2.41 million$261.02 million
Price / SalesN/AN/A20.65505.824.57
CashflowN/AN/AN/AN/A$1.67 per share
Price / CashN/AN/AN/AN/A7.03
Book Value$4.10 per share$9.29 per shareN/A($0.07) per share$3.38 per share
Price / BookN/AN/A-20.503.48
Profitability
Net Income$-161,870,000.00$-255,130,000.00$-630,000.00$-20,300,000.00$157.29 million
EPS($2.99)($13.98)N/AN/A$1.43
Trailing P/E RatioN/AN/A0.00N/A6.00
Forward P/E RatioN/AN/AN/A6.84
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A20.83%-2,658.66%67.16%
Return on Equity (ROE)-53.65%-88.73%16.55%N/A53.99%
Return on Assets (ROA)-49.11%-69.04%8.33%-47.19%28.92%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.26%N/AN/A0.72%
Current Ratio15.20%8.21%27.91%0.09%146.75%
Quick Ratio15.20%8.21%27.91%0.09%146.75%
Ownership Information
Institutional Ownership Percentage42.00%73.80%79.46%0.02%71.48%
Insider Ownership Percentage70.63%39.80%N/A21.30%0.32%
Miscellaneous
Employees1682578195
Shares Outstanding68.23 million31.32 million35.88 million849.50 million101.39 million
Next Earnings Date7/29/2021 (Estimated)5/11/2021 (Estimated)6/15/2021 (Estimated)6/23/2021 (Estimated)8/4/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
INVA Crosses Above Key Moving Average Level - NasdaqINVA Crosses Above Key Moving Average Level - Nasdaq
nasdaq.com - May 7 at 12:26 PM
Theravance Biopharma to Participate in an Upcoming Investor Conference - StockhouseTheravance Biopharma to Participate in an Upcoming Investor Conference - Stockhouse
stockhouse.com - May 6 at 6:23 AM
New Research: Anti-Asthmatic Drugs Market 2026 Industry Specifications and Outlook 2021| Abdi Ibrahim, Ception Therapeutics, Elan, Innoviva, Novartis, Sanofi – Clark County Blog - Clark County BlogNew Research: Anti-Asthmatic Drugs Market 2026 Industry Specifications and Outlook 2021| Abdi Ibrahim, Ception Therapeutics, Elan, Innoviva, Novartis, Sanofi – Clark County Blog - Clark County Blog
clarkcountyblog.com - May 5 at 11:39 PM
New Research: Anti-Asthmatic Drugs Market 2026 Industry Specifications and Outlook 2021| Abdi Ibrahim, Ception Therapeutics, Elan, Innoviva, Novartis, Sanofi – Clark County Blog - Clark County BlogNew Research: Anti-Asthmatic Drugs Market 2026 Industry Specifications and Outlook 2021| Abdi Ibrahim, Ception Therapeutics, Elan, Innoviva, Novartis, Sanofi – Clark County Blog - Clark County Blog
clarkcountyblog.com - May 5 at 11:39 PM
Entasis Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update - StreetInsider.comEntasis Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update - StreetInsider.com
streetinsider.com - May 5 at 6:38 PM
A Look At Innovivas (NASDAQ:INVA) Share Price Returns - Yahoo FinanceA Look At Innoviva's (NASDAQ:INVA) Share Price Returns - Yahoo Finance
finance.yahoo.com - May 5 at 1:38 PM
A Look At Innovivas (NASDAQ:INVA) Share Price ReturnsA Look At Innoviva's (NASDAQ:INVA) Share Price Returns
finance.yahoo.com - May 5 at 1:38 PM
Theravance Biopharma Inc (TBPH) Q1 2021 Earnings Call TranscriptTheravance Biopharma Inc (TBPH) Q1 2021 Earnings Call Transcript
fool.com - May 5 at 12:59 AM
Financings for May 4, 2021 | 2021-05-04 - BioWorld OnlineFinancings for May 4, 2021 | 2021-05-04 - BioWorld Online
bioworld.com - May 4 at 11:26 PM
Form 8-K Theravance Biopharma, For: May 04 - StreetInsider.comForm 8-K Theravance Biopharma, For: May 04 - StreetInsider.com
streetinsider.com - May 4 at 11:26 PM
Theravance Biopharma, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update - PRNewswireTheravance Biopharma, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update - PRNewswire
prnewswire.com - May 4 at 6:25 PM
Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva - GlobeNewswireEntasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva - GlobeNewswire
globenewswire.com - May 4 at 1:25 PM
Innoviva (NASDAQ:INVA) Lifted to "Hold" at Zacks Investment ResearchInnoviva (NASDAQ:INVA) Lifted to "Hold" at Zacks Investment Research
marketbeat.com - May 4 at 1:49 AM
Entasis completes initial closing of $20M private placement with Innoviva - Seeking AlphaEntasis completes initial closing of $20M private placement with Innoviva - Seeking Alpha
seekingalpha.com - May 4 at 12:50 AM
Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva - StreetInsider.comEntasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva - StreetInsider.com
streetinsider.com - May 3 at 7:50 PM
Entasis Therapeutics Completes Initial Closing of $20M Private Placement with InnovivaEntasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva
finance.yahoo.com - May 3 at 7:50 PM
Innoviva: Q1 Earnings SnapshotInnoviva: Q1 Earnings Snapshot
bradenton.com - May 3 at 9:21 AM
Should You Buy Innoviva Inc (INVA) Stock on Friday? - InvestorsObserverShould You Buy Innoviva Inc (INVA) Stock on Friday? - InvestorsObserver
investorsobserver.com - April 30 at 1:43 PM
Innoviva Stock Appears To Be Significantly Undervalued - Yahoo FinanceInnoviva Stock Appears To Be Significantly Undervalued - Yahoo Finance
finance.yahoo.com - April 30 at 8:07 AM
Innoviva Stock Appears To Be S - GuruFocus.comInnoviva Stock Appears To Be S - GuruFocus.com
gurufocus.com - April 30 at 1:43 AM
Innoviva (NASDAQ:INVA) Posts Quarterly  Earnings Results, Beats Expectations By $0.85 EPSInnoviva (NASDAQ:INVA) Posts Quarterly Earnings Results, Beats Expectations By $0.85 EPS
americanbankingnews.com - April 29 at 3:34 PM
Innoviva: Q1 Earnings Snapshot - Raleigh News & ObserverInnoviva: Q1 Earnings Snapshot - Raleigh News & Observer
newsobserver.com - April 29 at 10:40 AM
Innoviva Reports First Quarter 2021 Financial Results - Yahoo FinanceInnoviva Reports First Quarter 2021 Financial Results - Yahoo Finance
finance.yahoo.com - April 28 at 11:22 PM
Innoviva Reports First Quarter 2021 Financial Results - Business WireInnoviva Reports First Quarter 2021 Financial Results - Business Wire
businesswire.com - April 28 at 6:22 PM
Innoviva: Q1 Earnings Snapshot - San Francisco ChronicleInnoviva: Q1 Earnings Snapshot - San Francisco Chronicle
sfchronicle.com - April 28 at 6:22 PM
Innoviva Inc (INVA) Stock Decreases -1.93% This Week; Should You Buy? - InvestorsObserverInnoviva Inc (INVA) Stock Decreases -1.93% This Week; Should You Buy? - InvestorsObserver
investorsobserver.com - April 23 at 8:28 PM
DateCompanyBrokerageAction
11/24/2020Kiniksa PharmaceuticalsEvercore ISIInitiated Coverage
6/30/2020Kiniksa PharmaceuticalsThe Goldman Sachs GroupBoost Price Target
6/29/2020Kiniksa PharmaceuticalsBank of AmericaBoost Price Target
6/29/2020Kiniksa PharmaceuticalsWedbushBoost Price Target
3/11/2020Kiniksa PharmaceuticalsJPMorgan Chase & Co.Boost Price Target
8/14/2019Kiniksa PharmaceuticalsJMP SecuritiesLower Price Target
3/11/2019Kiniksa PharmaceuticalsBarclaysInitiated Coverage
2/17/2021Phathom PharmaceuticalsBMO Capital MarketsInitiated Coverage
2/2/2021Phathom PharmaceuticalsGuggenheimInitiated Coverage
1/28/2021Phathom PharmaceuticalsJonestradingInitiated Coverage
12/15/2020Phathom PharmaceuticalsNeedham & Company LLCBoost Price Target
11/27/2019Phathom PharmaceuticalsJefferies Financial GroupInitiated Coverage
4/26/2021Pliant TherapeuticsBTIG ResearchInitiated Coverage
4/22/2021Pliant TherapeuticsPiper SandlerBoost Price Target
4/5/2021Pliant TherapeuticsCitigroupInitiated Coverage
4/5/2021Pliant TherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
6/29/2020Pliant TherapeuticsCowenInitiated Coverage
5/29/2018Northwest BiotherapeuticsS&P Equity ResearchLower Price Target
11/11/2020InnovivaMorgan StanleyBoost Price Target
6/25/2018InnovivaStifel NicolausReiterated Rating
(Data available from 5/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.